Physician profile
Hung Dinh
NPI 1477280279
$8,469.60
in general payments reported to CMS, 2019-2025
36 companies · $2,981 in 2025
The $2,981 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $3,510 · 2024: $1,978 · 2025: $2,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,400 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,399.61 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,461.52 | 2023-2025 | |
| Ucb, INC. | $946.01 | 2023-2025 | Fintepla, Briviact, Rystiggo |
| Biogen, INC. | $815.38 | 2023-2025 | Vumerity, Leqembi, Tysabri |
| Argenx US, INC. | $542.17 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Amneal Pharmaceuticals LLC | $502.45 | 2023-2025 | Rytary, Crexont |
| Teva Pharmaceuticals USA, INC. | $500.08 | 2023-2025 | Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $406.49 | 2023-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $399.27 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $398.30 | 2024-2025 | |
| Livanova USA, INC. | $270.98 | 2023-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $269.06 | 2023-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $193.46 | 2023-2025 | Emgality, Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $184.35 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $160.47 | 2025 | Symbravo |
| Harmony Biosciences LLC | $159.98 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $128.90 | 2023 | Aptiom |
| Mdd US Operations, LLC | $113.07 | 2024-2025 | Gocovri |
| Eisai INC. | $103.04 | 2024-2025 | |
| Forte Bio-Pharma LLC | $91.94 | 2025 | Tanlor |
| Scilex Pharmaceuticals INC. | $83.49 | 2023 | Ztlido |
| Alexion Pharmaceuticals, INC. | $80.80 | 2024-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $80.36 | 2023-2025 | Hyqvia |
| Sk Life Science, INC. | $79.94 | 2024-2025 | |
| Kyowa Kirin, INC. | $58.55 | 2023 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $54.15 | 2023 | Dysport |
| Noven Therapeutics, LLC | $50.18 | 2025 | Xelstrym |
| Catalyst Pharmaceuticals, INC. | $46.03 | 2023-2024 | Firdapse |
| Emd Serono, INC. | $43.56 | 2024-2025 | |
| Merz Pharmaceuticals, LLC | $42.60 | 2023 | Xeomin |
| Azurity Pharmaceuticals, INC. | $39.02 | 2023 | Horizant |
| Tanabe Pharma America, INC. | $34.41 | 2023-2025 | Radicava |
| Genzyme Corporation | $31.41 | 2023 | |
| Janssen Biotech, INC. | $29.18 | 2025 | |
| Amgen INC. | $25.58 | 2023 | Aimovig |
| Amylyx Pharmaceuticals, INC. | $22.32 | 2023 | Relyvrio |
| Astrazeneca Pharmaceuticals LP | $21.10 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Dinh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.